FDA approves new, cheaper rival to EpiPen allergy shot

USA regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical company greed.

As a result of the increased prices of EpiPen, Mylan launched the first authorized generic for EpiPen Auto-Injector in Dec 2016 at a wholesale acquisition cost (WAC) of $300 per epinephrine injection USP two-pack, which is more than 50% lower than the WAC of EpiPen 2-Pak Auto-Injectors.

Mylan's EpiPen will soon have another lower-cost competitor to contend with. He also said the company was still in the process of looking for a distributor and is working on a price when the product goes on the market in the second half of this year.

Symjepi provides two prefilled, single-dose syringes of epinephrine (adrenaline), which is considered the drug of choice for immediate administration in acute anaphylactic reactions to insect stings or bites; in allergic reaction to foods (such as nuts), drugs, and other allergens; and in idiopathic or exercise-induced anaphylaxis.

While EpiPen has other rival products, doctors tend to prescribe EpiPen because it's so well known. Impax Laboratories' Adrenaclick device is being sold through CVS Health's drugstore chain for approximately $110 a pair.

Sanofi in April sued Mylan, accusing it of engaging in illegal practices to squash EpiPen competition when the French drugmaker held the Auvi-Q rights.

David Maris, an analyst at Wells Fargo, has been in touch with Adamis about its pricing and strategy, and he said the new product is likely to dent Mylan's business. The company said it would make the product available at no cost to many consumers but charge insurers $4,500.

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares were higher after the company unveiled a new allergy medication.

  • Zachary Reyes